论文部分内容阅读
目的:观察环磷酰胺冲击联合激素诱导缓解并维持治疗增殖型狼疮肾炎的疗效及不良反应。方法:将72例明确诊断为系统性红斑狼疮的增殖型肾小球肾炎患者随机分为静脉环磷酰胺组(治疗组n=36)、静脉环磷酰胺联合激素组(对照组n=36)。结果:平均随访36个月,治疗组的临床和实验室指标较对照组有显著的改善。治疗组感染发生率为34.1%,月经紊乱20.7%,骨髓抑制23.7%。结论:环磷酰胺冲击联合激素诱导缓解并维持治疗增殖性狼疮肾炎的疗效较好,但不良反应较对照组高。
Objective: To observe the efficacy and adverse reactions of cyclophosphamide combined with hormone-induced remission and maintenance of proliferative lupus nephritis. Methods: Seventy-two patients with proliferative glomerulonephritis diagnosed with systemic lupus erythematosus were randomly divided into intravenous cyclophosphamide group (n = 36 in treatment group), intravenous cyclophosphamide plus hormone group (n = 36 in control group) . Results: After a mean follow-up of 36 months, the clinical and laboratory parameters in the treatment group were significantly improved compared with the control group. Treatment group infection rate was 34.1%, menstrual disorders 20.7%, bone marrow suppression 23.7%. Conclusion: The effect of cyclophosphamide in combination with hormones to induce remission and maintain the treatment of proliferative lupus nephritis is better, but the adverse reaction is higher than that of the control group.